AeroLeads people directory · profile
Bill Bradley Email & Phone Number
Senior Director of Translational Research and Clinical Biomarkers
at
Antares Therapeutics
3 work emails found
@cyteir.com
2 phones found area 617
LinkedIn matched
✓ Verified July 2026
4 data sources
Profile completeness 100%
Current company
Role
Senior Director of Translational Research and Clinical Biomarkers
Location
Lexington, Massachusetts, United States
Who is Bill Bradley? Overview
A concise factual answer block for searchers comparing this professional profile.
Quick answer
Bill Bradley is listed as Senior Director of Translational Research and Clinical Biomarkers at Antares Therapeutics, based in Lexington, Massachusetts, United States. AeroLeads shows a work email signal at cyteir.com, phone signal with area code 617, and a matched LinkedIn profile for Bill Bradley.
Bill Bradley previously worked as Senior Director of Translational Research & Clinical Biomarkers at Scorpion Therapeutics and Senior Director, Head of Translational Research at Cyteir Therapeutics. Bill Bradley holds Ph.D., Molecular Biophysics & Biochemistry from Yale University.
Company email context
Email format at Antares Therapeutics
This section adds company-level context without repeating Bill Bradley's masked contact details.
{first}.{last}@cyteir.com
92% confidence
AeroLeads found 3 current-domain work email signals for Bill Bradley. Compare company email patterns before reaching out.
Profile bio
About Bill Bradley
▪ 10+ years of industry experience in big pharma and small biotech settings ranging from early discovery to phase 2 clinical development of molecularly targeted small molecule inhibitors in oncology therapeutic area▪ Experience building companies and departments, including leading a multifunctional team of scientists and associates, and building internal and external Translational Research department infrastructure▪ Track record of translating novel biological findings into differentiated clinical biomarker strategies as translational lead for 3 small molecule inhibitor clinical programs (MCT1 and 2 EZH2 inhibitors)▪ Preclinical oncology expertise, with practical experience in epigenetics, chromatin biology, kinases and signal transduction, synthetic lethality, immuno-oncology, and identification of mechanisms of therapeutic resistance▪ Success in establishing meaningful collaborations with key scientific leaders and clinical investigators
Listed skills include Cancer Research, Signal Transduction, Protein Kinases, Drug Discovery, and 11 others.
Current workplace
Bill Bradley's current company
Company context helps verify the profile and gives searchers a useful next step.
9 roles
Bill Bradley work experience
A career timeline built from the work history available for this profile.
Senior Director Of Translational Research & Clinical Biomarkers
Current
Apr 2024 - Present
Senior Director, Head Of Translational Research
- Discovered MOA of CYT-0851 as an inhibitor of monocarboxylate transporter (MCT) mediated lactate transport- Translational and biomarker lead for CYT-0851; implemented and managed biomarker strategy for phase 1/2 clinical trials in heme and solid cancers- Designed novel biomarker assays, including CTC- and ctDNA-based assay, and IHC, qPCR, and other NGS-based assays for both tumor and liquid biopsies- Built and managed Translational Research and Bioinformatics functions, and external In Vivo Pharmacology- Recruited and mentored 4 PhD scientists/associate directors; established and managed company’s external network of in vivo pharmacology, bioinformatics, and biomarker CRO’s and consultants, and SRA’s with academic collaborators- Supported executive leadership team during IPO (June 2021): writing scientific sections of S1, and writing/presenting responses to investors’ questions during crossover financing round
Feb 2022 - Jan 2024
Director, Head Of Translational Research
Feb 2020 - Feb 2022
Associate Director Of Translational Sciences
Constellation Pharmaceuticals
- Translational lead for EZH2 Inhibitor Franchise (lirametostat/CPI-1205 and tulmimetostat/CPI-0209)- Managed preclinical research group to understand MOA, expand indications, identify predictive and PD biomarkers, and mechanisms of resistance- Implemented biomarker strategy for CPI-1205 phase 1/2 clinical trials in metastatic castration-resistant prostate cancer, a combination trial with IO checkpoint inhibitors, and a non-Hodgkin’s B cell lymphoma trial- Worked with CSO to establish Translational Research function as a spin-out of Discovery Biology function- Supported executive leadership team during IPO (July 2018) contributing to scientific sections of S1
May 2017 - Feb 2020
Senior Scientist
Constellation Pharmaceuticals
- Co-managed preclinical biology for EZH2 inhibitor program- Discovered target engagement gene signature for EZH2 inhibitors; developed/implemented assays to establish PK/PD relationship for CPI-1205 including gene signature, IHC and CTC-based histone modification assays
Feb 2015 - May 2017
Scientist Ii
Constellation Pharmaceuticals
- Discovered synergistic combination of EZH2 inhibitors and type I interferons; explored clinical feasibility- Utilized multi-omics approach (RNA-/ChIP-seq) to advance understanding of EZH2’s role in cancer development through silencing of pro-apoptotic genes- Championed internal adoption of CETSA technique, CRISPR technology, and PRISM cell panel screening
Feb 2014 - Feb 2015
Scientist
Constellation Pharmaceuticals
- Preclinical biology lead for demethylase program during Genentech collaboration; coordinated research efforts with Genentech counterpart to support target validation, indication selection, and biomarker and stratification hypothesis generation
Oct 2012 - Feb 2014
Postdoctoral Fellow
- Member of preclinical vemurafenib team (Zelboraf, the first BRAF V600E-specific inhibitor approved for treatment of metastatic melanoma in August 2011) - Identified mechanism of acquired resistance to vemurafenib in melanoma cell lines- Generated model system to identify escape mechanisms utilized by melanoma to evade combination therapies- Investigated molecular basis of divergent vemurafenib efficacy observed between melanoma and colorectal cancers in human trials
Jan 2010 - Sep 2012
2 education records
Bill Bradley education
Ph.D., Molecular Biophysics & Biochemistry
Yale University
B.S., Biochemistry
Boston College
FAQ
Frequently asked questions about Bill Bradley
Quick answers generated from the profile data available on this page.
What company does Bill Bradley work for?
Bill Bradley works for Antares Therapeutics.
What is Bill Bradley's role at Antares Therapeutics?
Bill Bradley is listed as Senior Director of Translational Research and Clinical Biomarkers at Antares Therapeutics.
What is Bill Bradley's email address?
AeroLeads has found 3 work email signals at @cyteir.com for Bill Bradley at Antares Therapeutics.
What is Bill Bradley's phone number?
AeroLeads has found 2 phone signal(s) with area code 617 for Bill Bradley at Antares Therapeutics.
Where is Bill Bradley based?
Bill Bradley is based in Lexington, Massachusetts, United States while working with Antares Therapeutics.
What companies has Bill Bradley worked for?
Bill Bradley has worked for Antares Therapeutics, Scorpion Therapeutics, Cyteir Therapeutics, Constellation Pharmaceuticals, and Roche Pharmaceuticals.
How can I contact Bill Bradley?
You can use AeroLeads to view verified contact signals for Bill Bradley at Antares Therapeutics, including work email, phone, and LinkedIn data when available.
What schools did Bill Bradley attend?
Bill Bradley holds Ph.D., Molecular Biophysics & Biochemistry from Yale University.
What skills is Bill Bradley known for?
Bill Bradley is listed with skills including Cancer Research, Signal Transduction, Protein Kinases, Drug Discovery, Biochemistry, Molecular Biology, Cell Biology, and Target Identification.
Find 750M verified contacts
Search by job title, company, industry, location, and seniority. Export verified B2B contact data when you need it.
Start free trial